Category Archives: Immunology

Immunology

The SSC Platelet Immunology Register of VITT and VIITP: Towards standardization of laboratory and clinical parameters – DocWire News

This article was originally published here

J Thromb Haemost. 2021 Jun 2. doi: 10.1111/jth.15402. Online ahead of print.

ABSTRACT

A severe syndrome of thrombosis and thrombocytopenia has been described in patients vaccinated against severe acute respiratory distress syndrome coronavirus 2 (SARSCoV2) with a chimpanzee adenovirus vector encoding Spike protein (ChAdOx1 nCov-19, AstraZeneca).[1-6] as well as (Ad26.COV2.S, Johnson & Johnson/Janssen).[7] Currently, this novel immune thrombosis syndrome is known as vaccine-induced immune thrombotic thrombocytopenia (VITT) but has been described as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) and thrombotic thrombocytopenia syndrome (TTS) elsewhere.

PMID:34076338 | DOI:10.1111/jth.15402

More:
The SSC Platelet Immunology Register of VITT and VIITP: Towards standardization of laboratory and clinical parameters - DocWire News

Immunology

Global Precision Medicine Market, By Products and Services, – GlobeNewswire

New York, June 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Precision Medicine Market, By Products and Services, By Technology, By Application, By End User, By Region, Competition Forecast & Opportunities, 2026" - https://www.reportlinker.com/p05916716/?utm_source=GNW

Global precision medicine market was valued USD66.85 billion in 2020 and is expected to reach USD125.67 billion, growing at CAGR of 10.65% during the forecast period. Precision medicines are patient specific and vary from individual to individual. Increasing population and rising cancer cases in developing countries like India and China are the major factors propelling the growth of the precision medicine market. However, high price of precision medicines might hamper the growth of the market in the forecast period.

The global precision medicine market is segmented based on products and services, technology, application, end user, and region.The application segment is further divided into oncology, immunology, cardiology, neurology, respiratory and others.

Out of these, oncology held the largest market share in 2020 due to the increasing cases of cancer all over the world.

In terms of regional analysis, market is segregated into Asia-Pacific, North America, South America, Middle East & Africa and Europe.Among these, North America dominated the global precision medicine market until 2020 due to growing adoption of next generation sequencing methods in addition to favorable government policies.

Additionally, Asia-Pacific is anticipated to grow at the fastest CAGR due to the rising cases of cancer and other fatal diseases in the developing economies like India and China.

Major players in the global precision medicine market include IBM Watson Group, Roche Holding AG, Thermo Fischer Scientific Inc., Philips Healthcare Ltd., Illumina Inc., Quest Diagnostics Inc., Qiagen NV, AstraZeneca Plc, Agilent Technologies Inc., Novartis AG, NanoString Technologies Inc., NantHealth Inc., Orion Health Inc., Celcuity Inc., InsightRX Inc., and others. The companies are adopting various organic and inorganic strategies like, product launches, acquisitions and mergers to strengthen their position in the market. On 15th April 2021, Agilent Technologies, Inc. completed the acquisition of Resolution Bioscience, which is a leader in the development and commercialization of next-generation sequencing (NGS) based precision oncology solutions. Resolution Bioscience complements and expands Agilents capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market. Moreover, the addition of Resolution Biosciences liquid biopsy-based diagnostic technologies strengthens Agilents offerings to biopharma and clinical diagnostics customers and boosts growth opportunities in the companys diagnostics and genomics business.

Years considered for this report:

Historical Years: 2016-2019Base Year: 2020Estimated Year: 2021Forecast Period: 20222026

Objective of the Study:

To analyze historical growth in market size of global precision medicine market from FY2016 to FY2020. To estimate and forecast the market size of global precision medicine market from FY2021 to FY2026 and growth rate until FY2026. To classify and forecast global precision medicine market based on products and services, technology, application, end user, and region. To identify drivers and challenges for global precision medicine market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global precision medicine market. To conduct pricing analysis for global precision medicine market. To identify and analyze the profile of leading players operating in global precision medicine market.The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the manufacturers, distribution channels and presence of all major players across the globe.The analyst calculated the market size of global precision medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and Application for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Precision medicine manufacturers, suppliers, distributers and other stakeholders Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to precision medicine Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Global Precision Medicine Market, By Products and Services:o Precision Medicine Platformso Precision Medicine Toolso Precision Medicine Services Global Precision Medicine Market, By Technology:o Big Data Analyticso Artificial Intelligenceo Bioinformaticso Whole Genome Sequencingo Companion Diagnosticso Next Generation Sequencing (NGS)o Others Global Precision Medicine Market, By Application:o Oncologyo Immunologyo Cardiologyo Neurologyo Respiratoryo Others Global Precision Medicine Market, By End User:o Pharmaceutical and Biotechnology Companieso Healthcare ITo Diagnostic Companieso Clinical Research Organizationo Research Institutes Global Precision Medicine Market, By Region:o North AmericaUnited StatesCanadaMexicoo EuropeGermanyUnited KingdomFranceItalySpaino Asia-PacificChinaIndiaJapanSouth KoreaAustraliaSingaporeo South AmericaBrazilArgentinaColombiao Middle East & AfricaSouth AfricaSaudi ArabiaUAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global precision medicine market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five)Read the full report: https://www.reportlinker.com/p05916716/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more from the original source:
Global Precision Medicine Market, By Products and Services, - GlobeNewswire

Immunology

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas…

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

PARIS AND CAMBRIDGE, MA April 9, 2021 Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofis research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones. We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population, said Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi. We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions.

Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body. The technology delivers mRNA cargos selectively to designated types of cells in the body, with initial applications targeting specific types of immune cells. The in vivo approach is designed to provide similar efficacy to current ex vivo (outside the body) approaches where immune cells are genetically modified to enhance their therapeutic properties (such as chimeric antigen receptor [CAR]-expressing T-cells), with the potential for improved safety, outpatient dosing, and repeat dosing. Currently, Tidal Therapeutics has ongoing pre-clinical programs including in vivo re-programming of T cells or other types of immune cells for cancer indications.

Teaming up with Sanofi gives us the opportunity to further develop our unique platform and rapidly apply it to ultimately help patients across a range of diseases, said Ulrik Nielsen, President and CEO, Tidal Therapeutics.

About Tidal TherapeuticsTidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases. The company was seeded by Mission BioCapital, and joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundations venture philanthropy, MRL Ventures, and AbbVie Ventures.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Investor Relations Contacts ParisEva Schaefer-JansenArnaud Delepine

Investor Relations Contacts North AmericaFelix LauscherFara BerkowitzSuzanne Greco

IR main line:Tel.: +33 (0)1 53 77 45 45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact

Read more:
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas...

Immunology

Genomic testing services in pathology & immunology department to be expanded Washington University School of Medicine in St. Louis – Washington…

Visit the News Hub

Changes aimed at improving diagnosis of cancer, inherited diseases

The Department of Pathology & Immunology at Washington University School of Medicine in St. Louis is reorganizing and expanding its genomic medicine testing services to take advantage of advances in genetic and genomic sciences and improve clinical care.

Genetic and genomic testing is driving advances in precision medicine. Such testing provides the data that, when combined with information about disease status and environmental factors, enable doctors to move away from one-size-fits-all treatment plans to personalized therapies tailored to individual needs.

The Department of Pathology & Immunology at Washington University School of Medicine in St. Louis is reorganizing and expanding its genomic medicine testing services to take advantage of advances in genetic and genomic sciences and improve clinical care. Several new tests for cancer and inherited diseases are in the works. The department also is redesigning its website to make it easier for physicians to quickly identify the most appropriate tests for their patients.

As part of the reorganization, the department is establishing two new sections: a molecular oncology section, led by Eric Duncavage, MD, and an inherited diseases section, headed by Jonathan Heusel, MD, PhD.

The School of Medicine has been at the forefront of genetics research for many years, including leadership in whole genome sequencing, saidRichard Cote, MD, the Edward Mallinckrodt Professor and head of the Department of Pathology & Immunology. We have long had a major stake in translating these discoveries into clinically actionable tests to better define prognosis and treatment for a wide variety of diseases. We are delighted that Jon Heusel and Eric Duncavage, widely recognized for their research, are leading the effort to enhance the departments genetic and genomic testing services.

A wide variety of different mutations can give rise to cancer, and the specific mutations carried by a particular tumor affect its susceptibility to a particular treatment. These mutations also can be used to track a tumor during therapy to determine how it is responding to therapy. Clinical cancer genomics aims to use information on tumor mutations to help identify the therapies most likely to benefit the patient and avoid those least likely to help.

Duncavage

Duncavage and his Washington University colleagues recently developed a diagnostic test, ChromoSeq, for blood cancers, based on sequencing the whole genome. This comprehensive analysis has greater sensitivity than traditional testing, providing additional information that could help clinicians assess each patients risk of severe disease and choose the best treatment plan. The test was evaluated in a clinical trial of patients treated at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine. Results of that trial were published in March in The New England Journal of Medicine. ChromoSeq whole genome sequencing for blood cancers will be available as a clinical test through the Department of Pathology & Immunology.

Until recently, we could only analyze a limited set of genes or chromosomes because whole genome sequencing was too expensive for routine clinical use, Duncavage said. But recent advances in sequencing technologies and data analysis techniques have driven down the cost of whole genome sequencing in both time and resources. We showed that the technology could be used for blood cancers, and we are working on applying it to other kinds of cancers.

In addition, Heusel and Duncavage are spearheading an effort to develop tests to identify people with an inherited predisposition to cancer. Most famously, variations in the BRCA1 and BRCA2 genes increase the risk of breast and ovarian cancer, but dozens of other genes have been linked to a range of cancers. In the interest of efficiency, the tests under development are based on sequencing only the 2% of the genome that codes for proteins. This tiny fraction of the genome known as the exome is where nearly all mutations associated with disease risk are found.

Heusel

As chief of the inherited diseases section, Heusel will oversee the development and operation of tests for rare genetic diseases. Some of the people most in need of whole genome testing are babies born with mysterious ailments that appear to have genetic causes. Sequencing an affected newborns entire genome and often the genomes of both parents, too can be the fastest way to find an explanation for a babys condition.

Heusel and colleagues also are working on an improved test for disorders of somatic mosaicism, a group of conditions characterized by mutations in some cells but not others. Patients can have a wide range of symptoms, including overgrowth of one part of the body, such as the hand; skin spots or rashes; and abnormal tangles of blood vessels. The symptoms depend not only on what mutation has occurred but in which cells it has occurred. The researchers are building a faster, cheaper test that will allow more genes and more conditions to be screened.

Genetic testing particularly what we call next-generation sequencing, which involves sequencing dozens or hundreds of genes or whole exomes or whole genomes its transforming medicine, transforming the way we understand the basis of disease, how to diagnose it and how to treat it, Heusel said. What were really trying to do in the department now is make it easier for clinicians to take advantage of all the new genetic and genomic diagnostic tools that are becoming available.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Link:
Genomic testing services in pathology & immunology department to be expanded Washington University School of Medicine in St. Louis - Washington...

Immunology

Assistant/Associate/Full Professor of Veterinary Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 250949 – Times Higher…

Job Description

The United Arab Emirates University's College of Food & Agriculture invites applications for a faculty position in Microbiology with experience in Immunology and the One Health approach for the Department of Veterinary Medicine. Qualified candidates at all levels will be considered at a rank commensurate with academic accomplishments. Candidates are expected to have an understanding of veterinary education that will enable them to teach and coordinate courses in veterinary microbiology (virology, bacteriology, mycology) and immunology at both undergraduate and postgraduate levels as well as advise and mentor students. They should have a proven track record of demonstrable research capability that will enable the candidate to develop and sustain an internally and/or externally funded research program in his/her area of expertise and publish his/her research findings in international peer-reviewed scientific journals. The candidate will contribute to admissions, examining and assessment as well as academic administration in both the Department and the College, and actively promote the growth of the UAE University engaging in interdisciplinary collaboration with other UAEU colleges, e.g. College of Medicine and Health Sciences, College of Science, under the theme of One Health. The application package should include a cover letter, a detailed resume, a brief description of teaching philosophy and current/future research activities, as well as courses taught. English is the language of instruction and communication. Screening of applications will continue until the position is filled.

Minimum Qualification

Applicants must have an earned doctorate in Infectious Diseases, Virology, Bacteriology, Mycology, Immunology or similar field. The ability to teach undergraduate courses is a must. Industrial and professional experience is a plus. Good interpersonal and English oral and written communication skills are required, as is the ability to work with others in a diverse collegial team atmosphere.

Preferred Qualification

Candidates with a degree in veterinary medicine or comparable professional degree with documented accomplishments in teaching, research, and service are preferred. Additional qualifications of innovative and dynamic teaching or other professional skills relevant to a faculty role are desirable. Other evidence of working in One Health-related teaching and/or research especially in the Middle East and North Africa region as well as engagement in international-quality research, with publications and other participation in research activities commensurate with stage of career as well as a track record of securing research funding. Experience with AVMA accreditation requirements, and knowledge of innovative curriculum development and implementation is a plus.

Expected Skills/Rank/Experience

Rank and salary commensurate with accomplishments, expertise and experience. English fluency required. One Health-related teaching and/or research experience. Innovative and dynamic teaching or other professional skills. Record of research grantmaking and publications in international peer-reviewed journals.

Special Instructions to Applicant

Informal enquiries may be made to Prof Arve Lee Willingham (Chair, Department Veterinary Medicine) - awillingham@uaeu.ac.ae

Division College of Food & Agriculture-(CFA)Department Veterinary Medicine - (CFA)Job Close Date open until filledJob Category Academic - Faculty

See more here:
Assistant/Associate/Full Professor of Veterinary Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 250949 - Times Higher...

Immunology

IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology – Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--IM Therapeutics, Inc., a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases, announced today that David Alleva, Ph.D., has joined its management team as Vice President, Immunology. Dr. Alleva is an immunologist with deep experience in R&D in autoimmunity and infectious disease spanning 22 years and across early-stage biotech, foundations, and clinical-stage biopharmaceutical organizations.

IM Therapeutics IMT-HALT platform enables the development of oral small molecule drugs to block HLA gene variants as the earliest triggers of autoimmunity. The Companys lead drug candidate, IMT-002, is in a Phase 1b study in type 1 diabetes (T1D) in patients genetically preselected for HLA-DQ8. HLA-DQ8 significantly increases the risk for T1D and is present in 60% of T1D patients.

I am excited to welcome David to our leadership team and impressed by his work in novel approaches in T1D and the autoimmune spectrum, said Nandan Padukone, Ph.D., CEO of IM Therapeutics. David broadens our expertise at a pivotal time as we advance our lead program in T1D through Phase 1 clinical trials and progress our additional programs. Davids advocacy for new ways to treat T1D and his immunotherapy drug development experience will be tremendous assets to the company as we expand our autoimmune-targeted pipeline.

Dr. Alleva has been in senior R&D management positions, most recently at Akston Biosciences where he led immunotherapy development for T1D and a COVID-19 vaccine program. Previously, he led several R&D programs with ADiTx in T1D, managed portfolio programs at JDRF, and helped advance drug development of small-molecules, biologics, and vaccine therapeutics at Emergent BioSolutions, Hollis-Eden Pharmaceuticals, XOMA, and Neurocrine Biosciences.

Dr. Alleva earned a Ph.D. in immunology from the Virginia Polytechnic Institute and State University and performed postdoctoral autoimmune disease research at Boston University Medical Center. He has authored more than 30 peer-reviewed publications, has chaired immunology conferences, and is on the Editorial Board for the Biomedicines MDPI journal.

HLA drug targeting holds great promise and I am very excited by the progress made by IM Therapeutics to tap into this genetically-directed approach for T1D and other autoimmune diseases, said Dr. Alleva. I look forward to joining this dynamic team and bringing forward new personalized medicines to treat the underlying biology of autoimmunity.

About IMT-002

IMT-002, the lead drug candidate of IM Therapeutics, is the first oral genetically targeted drug candidate to be tested in T1D patients, an incurable autoimmune disorder that affects nearly 1.6 million people in the United States. IMT-002 completed a Phase 1a study in 2020 and is currently completing a Phase 1b study in T1D patients preselected for the HLA-DQ8 gene variant. IMT-002 is designed to block HLA-DQ8 to prevent the immune system from attacking insulin-producing beta cells, thereby preserving function in newly diagnosed patients, and is being investigated as a once- or twice-daily drug candidate. Previous studies of a tool drug, L-methyldopa, which is FDA-approved for treating hypertension, in a Phase 1b study, showed effective inhibition of HLA-DQ8 activity in new onset type 1 diabetes patients who had the HLA-DQ8 gene variant. Several in vivo IND-enabling studies indicate that IMT-002, which unlike the tool drug, is not metabolized physiologically, has more potency to block HLA-DQ8 activity and a favorable safety profile.

About IM Therapeutics

IM Therapeutics is a clinical-stage company pioneering personalized, oral medicines that target human leukocyte antigen (HLA) gene variants to treat the root cause of autoimmune diseases. The Companys IMT-HALT platform enables the development of small molecule drugs using in silico docking of millions of compounds into pockets of an HLA variant where self-antigens may bind to trigger autoimmunity. Selected drug hits are then optimized using proprietary structure-based design and activity screening with cell-based assays for specificity of HLA inhibition. Lead drugs developed against an HLA variant have the ability to block a series of self-antigens and therefore the potential to treat a range of autoimmune diseases related to a selected HLA. The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus. Learn more at http://www.IMTherapeutics.com.

See the original post here:
IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology - Business Wire

Immunology

Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development, Upcoming Webinar Hosted by Xtalks – PR Web

This talk will outline when to consider different I&I assay services and the regulatory and scientific considerations for these that will influence the appropriate biological interpretation of the immune response.

TORONTO, Ontario (PRWEB) April 06, 2021

There are many considerations for Immunology and Immunotoxicology (I&I) assessments that are needed during the early phase of drug development. This talk will outline when to consider different I&I assay services and the regulatory and scientific considerations for these that will influence the appropriate biological interpretation of the immune response.

Register for this live webinar taking place on Monday, April 19, 2021 at 9am EDT (2pm BST/UK) to hear a talk given by experts from Covance by Labcorp, James Munday, PhD, EU Lead, Immunology & Immunotoxicology; and Chris Cooper, Subject Matter Expert, Manager. They will give an outline of how to perform the appropriate safety assessments to show that there is no adverse immunotoxicology associated with the development of new therapeutic entities.

For more information, or to register for this event, visit Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:Ayesha RashidTel: +1 (416) 977-6555 x 272Email: arashid@xtalks.com

Share article on social media or email:

Excerpt from:
Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development, Upcoming Webinar Hosted by Xtalks - PR Web

Immunology

LSU Health Shreveport awarded over $10.5 million for a NIH COBRE research grant focused on better understanding the immune system and how diseases…

LSU Health Shreveport has received a 5-year grant for $10,529,128 from the National Institutes of Health (NIH) to establish a new Center of Biomedical Research Excellence or COBRE. The grant has two-five year renewal options.

Funding from the COBRE grant will be utilized to create the Center for Applied Immunology and Pathological Processes (CAIPP). Dr. Andrew D. Yurochko, Professor and Carroll Feist Endowed Chair of Viral Oncology; Vice-Chair of Microbiology and Immunology, and Director of the Center of Excellence for Emerging Viral Threats is the principal investigator for the grant and will be the director of the new center. Serving as senior faculty members and directors or chairs of the key COBRE cores of this new Center for Applied Immunology and Pathological Processes (CAIPP) are:

Dr. Rona S. Scott, Associate Professor and Mingyu Ding Professor of Microbiology and Immunology (will serve as Director of the Bioinformatics/Modeling Core),

Dr. Matthew D. Woolard, Associate Professor and OCallaghan Family Endowed Professor in Microbiology (will serve as Director of the Immunophenotyping Core), and

Dr. Martin J. Sapp, Department Chair and Professor of Microbiology and Immunology and Willis Knighton Chair of Molecular Biology (will Chair the Junior Faculty Mentoring Committee).

Serving as the first of the key junior research faculty for the CAIPP are:

Dr. Xiaohong Lu, Assistant Professor of Pharmacology, Toxicology and Neuroscience,

Dr. Ana Dragoi, Assistant Professor of Molecular and Cellular Physiology, and

Dr. Monica Cartelle Gestal, Assistant Professor of Microbiology and Immunology.

This third COBRE at LSU Health Shreveport will provide an interactive training and research environment for young investigators in the field of immunology, as well as allow them to receive the mentorship and guidance needed to increase their competitiveness for national funding. The goal of all COBRE grants is to grow, recruit and retain new talent; expand existing research; and develop robust infrastructure that encourages statewide collaboration.

Read more:
LSU Health Shreveport awarded over $10.5 million for a NIH COBRE research grant focused on better understanding the immune system and how diseases...